Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2005

View Archived Issues

Abzymes --a new drug target for atherosclerosis treatment

Pradefovir reduces viral load of patients with chronic hepatitis B

Therapeutic benefits of mometasone furoate spray in nasal polyposis

SLV-323 demonstrates certain antidepressant-like activity in vivo / News in Context

Antitumor responses in lung cancer induced by COX-2 inhibition

Emezine NDA accepted for review

Oral low-dose interferon alpha to be studied for Behcet's disease

FDA advisory panel recommends continued availability of Serevent

Phase IIb trial of cetilistat in obese diabetics completes enrollment

Cilag to acquire European nesiritide rights from GlaxoSmithKline

BEYOND study of Betaferon completes enrollment

Approval of Onyx for treatment of arteriovenous malformations

Update on the clinical effects of ciclesonide in asthma

ABT-751 shows promise in the treatment of advanced NSCLC

RC-1291 enters phase II for cachexia in cancer patients

Clinical trials evaluate TLK-286 plus chemotherapy as first-line therapy for advanced NSCLC

RC-8800 for prostate cancer enters clinical testing

New data on the pharmacokinetics and safety of S-3304 in healthy subjects

Therapeutic agents for osteoporosis jointly reported by Novartis and Signal researchers

Motexafin gadolinium under phase I clinical evaluation in NSCLC

New treatments for cancer covered in recent patents

Phase III Parkinson's disease study of safinamide completes enrollment

Recent patents disclose novel agents for treating diabetes

Epilepsy Foundation of America welcomes use of VNS Therapy

Evotec and Almirall sign library synthesis agreement

Enrollment completed in low dose arm of Trinam phase II study